University of Hertfordshire

View graph of relations
Original languageEnglish
Publication statusPublished - 2012
EventRoyal Statistical Society International Conference - Telford, United Kingdom
Duration: 3 Sep 20126 Sep 2012


ConferenceRoyal Statistical Society International Conference
CountryUnited Kingdom


In Oncology drug development, the great majority of phase 3 trials are negative.. New strategies are required to rapidly identify novel agents prior to large randomised trials. The CA125 doubling trial successfully showed that an effective drug could be identified more efficiently by testing whether the rate of increase in the tumour marker CA125 decreased after starting the novel agent, at a point identified by CA125 rising to four times it’s nadir level. However efficiency could be improved, if more patients could be included. This work explores identifying an earlier effective starting point by analysing the time course of CA125 rise.

Research outputs

ID: 2319037